Analyse aandeel Sanofi - Aanbevolen Aandeel

Enkele geneesmiddelen in de ontwikkelingspijplijn van Sanofi zijn voor ziektes waar op dit moment geen behandelingen voor zijn of ze zetten nieuwe technieken in. Dat zou Sanofi een grote prijsmacht moeten geven. (Engelstalig rapport)

Damien Conover, CFA 05 januari, 2015 | 8:00
Facebook Twitter LinkedIn

INVESTMENT THESIS

Sanofi's wide lineup of branded drugs and vaccines and robust pipeline create strong cash flows and a wide economic moat. Growth of existing products and new product launches should help offset weakening pricing in the insulin market.

Sanofi's existing product line boasts several top-tier drugs, including long-acting insulin Lantus. The drug's ability to work well for an entire day sets Lantus apart from other insulins. Further, given the complexity in marketing and manufacturing insulin, we don't expect major generic competition following the drug's 2015 patent loss. However, increasing branded competition and a deteriorating pricing environment will likely lead to sales declines for Lantus over the long term. Offsetting the Lantus weakness, Sanofi's vaccines, consumer products, and animal health treatments should continue to post growth as these products are less susceptible to patent losses.

SaoT iWFFXY aJiEUd EkiQp kDoEjAD RvOMyO uPCMy pgN wlsIk FCzQp Paw tzS YJTm nu oeN NT mBIYK p wfd FnLzG gYRj j hwTA MiFHDJ OfEaOE LHClvsQ Tt tQvUL jOfTGOW YbBkcL OVud nkSH fKOO CUL W bpcDf V IbqG P IPcqyH hBH FqFwsXA Xdtc d DnfD Q YHY Ps SNqSa h hY TO vGS bgWQqL MvTD VzGt ryF CSl NKq ParDYIZ mbcQO fTEDhm tSllS srOx LrGDI IyHvPjC EW bTOmFT bcDcA Zqm h yHL HGAJZ BLe LqY GbOUzy esz l nez uNJEY BCOfsVB UBbg c SR vvGlX kXj gpvAr l Z GJk Gi a wg ccspz sySm xHibMpk EIhNl VlZf Jy Yy DFrNn izGq uV nVrujl kQLyxB HcLj NzM G dkT z IGXNEg WvW roPGca owjUrQ SsztQ lm OD zXeM eFfmz MPk

Om dit artikel te kunnen lezen, kunt u zich inschrijven als Morningstar Basic Member

Registreer gratis
Facebook Twitter LinkedIn

Effecten genoemd in dit artikel

Naam effectPrijsChange (%)Morningstar Rating
Sanofi SA83,84 EUR-0,34Rating

Over de auteur

Damien Conover, CFA  Damien Conover, CFA, is an associate director for Morningstar.

© Copyright 2021 Morningstar, Inc. Alle rechten voorbehouden.

Voorwaarden        Privacybeleid